Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck and : WHO to start treatment with Merck's Ebola vaccine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/18/2018 | 05:56am EDT

The World Health Organization said Thursday it plans to begin administering Ebola vaccine rVSV-ZEBOV (V920) in the Democratic Republic of the Congo "as soon as possible." WHO noted that 4,300 doses of the Merck & Co. Inc. (NYSE:MRK) vaccine are already in the region and an additional 7,540 doses are being shipped to the African nation.

The vaccine is being given as part of an expanded access protocol, according to Merck, which has a stockpile of more than 300,000 emergency use dose equivalents. WHO declared the situation an "outbreak" on May 8 (see BioCentury Extra, May 14).

WHO also reported on Thursday five additional Ebola cases, including one confirmed case in the Wangata health zone of Mbandaka, a city of nearly 1.5 million people. The two prior confirmed Ebola cases were in the town of Bikoro, about 150 km away from Mbandaka. So far, there have been 44 reported cases of Ebola virus disease.

rVSV-ZEBOV is a recombinant vesicular stomatitis virus (rVSV) vaccine expressing an Ebola virus protein.

Final data from a 11,841-subject Phase III ring vaccination trial published in 2016 in The Lancet showed that rVSV-ZEBOV led to no Ebola cases after 10 or more days postvaccination compared with 23 cases in subjects who did not receive the vaccine. Subjects were followed for 84 days.

The vaccine was originally developed by the Public Health Agency of Canada, which retains non-commercial rights under a 2010 deal granting NewLink Genetics Corp. (NASDAQ:NLNK) rights to the product. Merck has exclusive, worldwide rights to develop, commercialize and manufacture the vaccine from NewLink under a 2014 deal (see BioCentury Extra, Nov. 24, 2014).

.

(C) 2018 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
MERCK AND COMPANY 0.21% 82.08 Delayed Quote.7.42%
NEWLINK GENETICS CORP -0.47% 2.13 Delayed Quote.40.13%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
07:47aMERCK AND : NGM Bio Extend Therapeutics Collaboration to 2022
DJ
06:31aMERCK : and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaborat..
BU
02:48aBRISTOL MYERS SQUIBB : Overheard
DJ
03/19BRISTOL MYERS SQUIBB : Correction to Bristol-Myers Squibb Overheard Article
DJ
03/19If This Is Failure, Show Me Success -- Overheard
DJ
03/18MERCK AND : New Treatment Option Now Available in Canada for Newly Diagnosed Pat..
AQ
03/16ROCHE : Key drugs from Merck, Roche win wider EU approvals
AQ
03/15MERCK AND : Amended tender offer statement by Third Party
PU
03/14MERCK AND : UK Monopoly Watchdog Closes Investigation on Merck & Co Subsidiary
DJ
03/14MERCK AND : European Commission Approves Merck's KEYTRUDA® (pembrolizumab) in Co..
BU
More news
Financials ($)
Sales 2019 44 654 M
EBIT 2019 14 986 M
Net income 2019 9 947 M
Debt 2019 16 436 M
Yield 2019 2,69%
P/E ratio 2019 20,77
P/E ratio 2020 17,61
EV / Sales 2019 5,10x
EV / Sales 2020 4,79x
Capitalization 211 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 85,5 $
Spread / Average Target 4,4%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY7.42%211 428
JOHNSON & JOHNSON7.28%368 634
NOVARTIS10.80%237 206
PFIZER-3.09%234 841
ROCHE HOLDING LTD.10.93%232 383
ELI LILLY AND COMPANY9.39%131 074